ERBB2 and breast carcinoma: Importantly, using five luminal organoid models and one non‐luminal control organoid (ER−/PR−/HER2+) derived from breast cancer (Cosgrove et al, 2022; Guillen et al, 2022), we successfully validated our cell line‐based observations (Figs 4G and EV6H).